Seminars in oncology

publication venue for

Recommend upfront consolidation with high-dose melphalan and autologous stem cell support. 2016
Treatment of high-risk smoldering myeloma. 2016
Deferring autologous stem cell transplantation for consolidation of minimal residual disease in multiple myeloma. 2016
Low-grade follicular lymphoma of the small intestine: a challenge for management. 2011
Gastric mucosa-associated lymphoid tissue lymphoma. 2010
The role of anti-tumor necrosis factor receptor agents in cancer survivors: does the risk justify the benefit? 2010
Completely regressed cutaneous melanocytic lesion: was it benign or was it malignant? 2009
Psychosocial aspects of head and neck cancer. 1988
A double-edged sword: Prolonged detection of SARS-COV-2 in patients receiving cancer directed therapy.. 48. 2020
Commentary: Somatostatin analogs-How we choose, and why.. 44. 2017
The future of clinical cancer genomics.. 43. 2016
Characterization and management of dermatologic adverse events with the NovoTTF-100A System, a novel anti-mitotic electric field device for the treatment of recurrent glioblastoma.. 41 Suppl 4. 2014
Health disparities and the cancer survivor.. 40. 2013
Renal and pulmonary late effects of cancer therapy.. 40. 2013
Quantitative ultrasound in cancer imaging.. 38. 2011
Readers' responses to "Breast cancer with positive sentinel lymph node: now what?".. 37. 2010
Whither TNM?. 37. 2010
Janus kinase mutations.. 36. 2009
Radical cystectomy and lymphadenectomy for invasive bladder cancer: towards the evolution of an optimal surgical standard.. 34. 2007
Are cancers of the esophagus, gastroesophageal junction, and cardia one disease, two, or several?. 31. 2004
Missed micrometastatic disease in breast cancer.. 31. 2004
Treatment of Waldenstrom's macroglobulinemia with clarithromycin, low-dose thalidomide, and dexamethasone.. 30. 2003
Using technology to decrease xerostomia for head and neck cancer patients treated with radiation therapy.. 29. 2002
Early results of a randomized phase III trial of platinum-containing doublets versus a nonplatinum doublet in the treatment of advanced non-small cell lung cancer: European Organization for Research and Treatment of Cancer 08975.. 29. 2002
Immunotherapy of non-Hodgkin's lymphoma with hLL2 (epratuzumab, an anti-CD22 monoclonal antibody) and Hu1D10 (apolizumab).. 29. 2002
Docetaxel (Taxotere) in the treatment of non-small cell lung cancer: an international update.. 28. 2001
Renal cell carcinoma: progress against an elusive tumor.. 27. 2000
Introduction: colorectal cancer: past accomplishments and future directions I.. 26. 1999
Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer.. 26. 1999
Docetaxel (Taxotere) in the treatment of non-small cell lung cancer.. 26. 1999
What does chemotherapy have to offer patients with advanced-stage non-small cell lung cancer?. 25. 1998
Primary chemotherapy for breast cancer: hope or hype?. 25. 1998
A phase II trial of paclitaxel and cisplatin in patients with locally advanced metastatic esophageal cancer: a preliminary report.. 24. 1997
Phase I/II study of paclitaxel/cisplatin as first-line therapy for locally advanced head and neck cancer.. 24. 1997
Dose-dense therapy with paclitaxel via weekly 1-hour infusion: preliminary experience in the treatment of metastatic breast cancer.. 24. 1997
Paclitaxel in salvage therapy for germ cell tumors.. 24. 1997
Salvage weekly paclitaxel in recurrent ovarian cancer.. 24. 1997
Induction paclitaxel/carboplatin in early stage non-small cell lung cancer. Bimodality Lung Oncology Team.. 24. 1997
Innovative approaches to the treatment of advanced breast cancer: introduction.. 24. 1997
The development of docetaxel (Taxotere) in non-small cell lung cancer.. 24. 1997
Clinical pharmacology of carboplatin administered in combination with paclitaxel.. 24. 1997
Dose escalation of paclitaxel with high-dose carboplatin using peripheral blood progenitor cell support in patients with advanced ovarian cancer.. 24. 1997
Prognostic models in melanoma.. 24. 1997
Study of escalating doses of paclitaxel plus cisplatin in patients with inoperable head and neck cancer.. 24. 1997
Paclitaxel in the treatment of patients with upper gastrointestinal carcinomas.. 23. 1996
Results of the phase II EORTC study comparing paclitaxel/cisplatin with teniposide/cisplatin in patients with non-small cell lung cancer. EORTC Lung Cancer Cooperative Group.. 23. 1996
Sequential adjuvant therapy: the Memorial Sloan-Kettering Cancer Center experience.. 23. 1996
Sequential adjuvant therapy with doxorubicin/paclitaxel/cyclophosphamide for resectable breast cancer involving four or more axillary nodes.. 22. 1995
The activity of paclitaxel in gastrointestinal tumors.. 22. 1995
Dose-finding and sequencing study of paclitaxel and carboplatin in non-small cell lung cancer.. 22. 1995
Memorial Sloan-Kettering Cancer Center experience with paclitaxel in the treatment of breast cancer: from advanced disease to adjuvant therapy.. 22. 1995
Paclitaxel in the treatment of carcinoma of the esophagus.. 22. 1995
A phase II trial of paclitaxel (Taxol) in advanced esophageal cancer: preliminary report.. 21. 1994
Etoposide plus carboplatin or cisplatin in good-risk patients with germ cell tumors: a randomized comparison.. 21. 1994
Introduction: prostate cancer.. 21. 1994
Preliminary results of two dose-finding studies of paclitaxel (Taxol) and carboplatin in non-small cell lung and ovarian cancers: a European Cancer Centre effort.. 21. 1994
Brachytherapy and hyperthermia for malignant astrocytomas.. 21. 1994
Preliminary experience with paclitaxel (Taxol) plus recombinant human granulocyte colony-stimulating factor in the treatment of breast cancer.. 20. 1993
Exploring the use of chronic low-dose oral etoposide in ovarian cancer: is there a role for this "new drug" in the management of platinum-refractory disease?. 19. 1992
Ifosfamide-based chemotherapy for patients with resistant germ cell tumors: the Memorial Sloan-Kettering Cancer Center experience.. 19. 1992
A phase II pilot trial of high-dose hydroxyurea in chronic myelogenous leukemia.. 19. 1992
Alfa-2A interferon and 5-fluorouracil for advanced colorectal carcinoma: the Memorial Sloan-Kettering experience.. 19. 1992
The European Organization for Research and Treatment of Cancer experience with teniposide: preliminary results of a randomized study in non-small cell lung cancer.. 19. 1992
Can we combine available data to evaluate the effects of neoadjuvant chemotherapy for invasive bladder cancer?. 17. 1990
Chemotherapy for invasive bladder cancer: introduction.. 17. 1990
High-dose thiotepa alone and in combination regimens with bone marrow support.. 17. 1990
Idarubicin in acute leukemia: results of studies at Memorial Sloan-Kettering Cancer Center.. 16. 1989
The European Organization for Research and Treatment of Cancer (EORTC) trials of new agents for advanced non-small cell lung cancer.. 15. 1988
Identification and management of poor risk patients with germ cell tumors: the Memorial Sloan-Kettering Cancer Center experience.. 15. 1988
Bone marrow transplantation for acute leukemia and lymphoma with high-dose cytosine arabinoside and total body irradiation.. 14. 1987
Intensive postremission therapy in adults with acute nonlymphocytic leukemia using various dose schedules of ara-C: a progress report from the CALGB. Cancer and Leukemia Group B.. 14. 1987
Hairy cell leukemia: a model for studying the B cell family of diseases.. 13. 1986
Medical oncology manpower training: a position statement of the American Society of Clinical Oncology.. 12. 1985
Bone marrow transplantation for acute leukemia and lymphoma with high-dose cytosine arabinoside and total body irradiation.. 12. 1985
Intensive postremission therapy in adults with acute nonlymphocytic leukemia with ara-C by continuous infusion or bolus administration: preliminary results of a CALGB phase I study.. 12. 1985
The diagnosis of gastric cancer.. 12. 1985
Nutritional support of the patient with esophageal cancer.. 11. 1984
Indications for surgery for intrathoracic metastases in testicular carcinoma.. 6. 1979
External radiotherapy of ovarian cancer: standard approaches and new frontiers.. 2. 1975
Inflammatory breast cancer: defining a new entity.. 35. 2008
Treatment recommendations in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. 2003
New Approaches to the Treatment of Cancer-Related Anemia. Symposium proceedings. New York, October 23, 1993. 1994
Cancer in older adults: the oncologist's bread and butter.. 35. 2008
The evolution of bladder cancer treatment: improvements in clinical management, enhanced clinical outcomes, and targeting newly identified molecular alterations.. 34. 2007
Optimizing cancer chemotherapy and hormonal therapy: the key role of supportive agents. Introduction.. 31. 2004
Esophageal cancer.. 21. 1994
Adverse events of different chemotherapy regimens in the first-line treatment of patients with advanced or metastatic urothelial cancer: A systematic review and network meta-analysis of randomized controlled trials. 2021
Implications of reactive oxygen species on cancer formation and its treatment. 2021
Biomarker-Driven and Molecular Targeted Therapies for Hepatobiliary Cancers. 2018
Controversies in multiple myeloma: Evidence-based update. 2016
ASCO Plenary Sessions: impact, legacy, future. 2016
Targeting obesity-related adipose tissue dysfunction to prevent cancer development and progression. 2015
A 46-Year-Old Asian Woman With Liver Mass. 2015
Clinical Activity, Toxicity, Biomarkers, and Future Development of CTLA-4 Checkpoint Antagonists. 2015
Adjuvant and neoadjuvant systemic therapy for pancreas adenocarcinoma. 2014
GD2-targeted immunotherapy and radioimmunotherapy. 2014
Cancer survivorship: cardiotoxic therapy in the adult cancer patient; cardiac outcomes with recommendations for patient management. 2013
Cognitive effects of cancer and its treatments at the intersection of aging: what do we know; what do we need to know? 2013
Energy balance and metabolism after cancer treatment. 2013
Sexual and reproductive health in cancer survivors. 2013
Evolving strategies in the initial treatment of multiple myeloma. 2013
Myeloma: classification and risk assessment. 2013
Systemic treatment options for untreated patients with metastatic clear cell renal cancer. 2013
Monitoring the clinical outcomes in advanced prostate cancer: what imaging modalities and other markers are reliable? 2013
Perspectives on immunotherapy in prostate cancer and solid tumors: where is the future? 2013
Exercise therapy as treatment for cardiovascular and oncologic disease after a diagnosis of early-stage cancer. 2013
Managing the risks of cardiac therapy in cancer patients. 2013
The management of extrapulmonary poorly differentiated (high-grade) neuroendocrine carcinomas. 2013
Immune tolerance and transplantation. 2012
MicroRNAs in mutagenesis, genomic instability, and DNA repair. 2011
Molecular biology of myelodysplastic syndromes. 2011
An update on cancer- and chemotherapy-related cognitive dysfunction: current status. 2011
Approved agents for metastatic breast cancer. 2011
Personalized treatment of lymphoma: promise and reality. 2011
Molecular imaging of neuroendocrine tumors. 2010
Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy. 2010
Maintaining bone health in prostate cancer throughout the disease continuum. 2010
Zoledronic acid use in patients with bone metastases from renal cell carcinoma or bladder cancer. 2010
Regional hepatic chemotherapies in treatment of colorectal cancer metastases to the liver. 2010
Traditional statistical methods for evaluating prediction models are uninformative as to clinical value: towards a decision analytic framework. 2010
Colorectal cancer in young adults. 2009
Gastrointestinal stromal tumors I: pathology, pathobiology, primary therapy, and surgical issues. 2009
Surgical management of recurrent ovarian cancer. 2009
Cognitive effects of hormonal therapy in older adults. 2008
Management of prostate cancer in the older man. 2008
Ovarian cancer in older women. 2008
Defining the clinical diagnosis of inflammatory breast cancer. 2008
Optimizing outcomes for patients with advanced disease in chronic myelogenous leukemia. 2008
The medical treatment of inflammatory breast cancer. 2008
Melanoma vaccines. 2007
Purine nucleoside phosphorylase inhibition as a novel therapeutic approach for B-cell lymphoid malignancies. 2007
The molecular basis of melanomagenesis and the metastatic phenotype. 2007
Ethical and legal aspects of cancer genetic testing. 2007
Familial colorectal cancer syndrome X. 2007
Treatment of hereditary breast cancer. 2007
Cytotoxic therapy for advanced pancreatic adenocarcinoma. 2007
New generation of molecular prognostic and predictive tests for breast cancer. 2007
Perioperative chemotherapy in muscle-invasive bladder cancer to enhance survival and/or as a strategy for bladder preservation. 2007
Urinary diversion: options, patient selection, and outcomes. 2007
Small cell carcinomas of the gastrointestinal tract: clinicopathological features and treatment approach. 2007
Adjuvant therapy with aromatase inhibitors for postmenopausal women with early breast cancer: evidence and ongoing controversy. 2006
Hepatocellular carcinoma: molecular biology and therapy. 2006
Planned treatment interruptions and chemotherapy-free intervals in the treatment of metastatic colorectal cancer: time to start stopping? 2006
The pathology of renal epithelial neoplasms. 2006
Circulating tumor cells, disease progression, and survival in metastatic breast cancer. 2006
Neurologic complications of cancer chemotherapy. 2006
The role of alemtuzumab in nonmyeloablative hematopoietic transplantation. 2006
Multimodality therapy of local regional esophageal cancer. 2005
Hematopoietic stem cell transplantation for myelofibrosis. 2005
Clinical update: novel targets in gynecologic malignancies. 2004
Treatment of primary central nervous system lymphoma. 2004
Treatment of localized esophageal cancer. 2004
Treatment of metastatic esophagus and gastric cancer. 2004
COX-2 inhibition in upper aerodigestive tract tumors. 2004
Nonmyeloablative reduced-intensity transplantation in multiple myeloma. 2004
Benefits of adjuvant chemotherapy in high-grade gliomas. 2003
Cardiac effects of adjuvant therapy for early breast cancer. 2003
The impact of adjuvant therapy for breast cancer on cognitive function: current evidence and directions for research. 2003
Advances in imaging in the postoperative patient with a rising prostate-specific antigen level. 2003
DNA vaccines: an active immunization strategy for prostate cancer. 2003
Hsp90 as a therapeutic target in prostate cancer. 2003
Predicting clinical end points: treatment nomograms in prostate cancer. 2003
Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen. 2003
Technological advances in external-beam radiation therapy for the treatment of localized prostate cancer. 2003
CD22-directed monoclonal antibody therapy for lymphoma. 2003
Development of the epidermal growth factor receptor inhibitor OSI-774. 2003
Pharmacokinetics and pharmacodynamics: maximizing the clinical potential of Erlotinib (Tarceva). 2003
Recommendations of follow-up after treatment of germ cell tumors. 2003
A clinical and scientific overview of tositumomab and iodine I 131 tositumomab. 2003
Autologous and allogeneic stem cell transplantation in Waldenstrom's macroglobulinemia: review of the literature and future directions. 2003
Gallium nitrate in multiple myeloma: prolonged survival in a cohort of patients with advanced-stage disease. 2003
Monotherapy options in the management of metastatic breast cancer. 2003
The effects of gallium nitrate on bone resorption. 2003
Targeting lethal minimal residual disease in small cell lung cancer. 2003
Expanding horizons: an update on the use of docetaxel in non-small cell lung, ovarian, and breast cancers. 2002
Intrahepatic arterial infusion of chemotherapy: clinical results. 2002
Angiogenesis inhibitors in clinical development for lung cancer. 2002
Immunotherapy of non-Hodgkin's lymphoma with hLL2 (epratuzumab, an anti-CD22 monoclonal antibody) and Hu1D10 (apolizumab). 2002
Trastuzumab in the treatment of non-small cell lung cancer. 2002
Breast cancer imaging: the future. 2001
New drug and multimodality combinations in the treatment of advanced non--small cell lung cancer. 2001
Adjuvant therapy of colon cancer. 2001
Docetaxel (Taxotere) shows survival and quality-of-life benefits in the second-line treatment of non-small cell lung cancer: a review of two phase III trials. 2001
A potential role for activated HER-2 in prostate cancer. 2000
Overview of idiopathic thrombocytopenic purpura: new approach to refractory patients. 2000
Trastuzumab in combination with chemotherapy for the treatment of metastatic breast cancer. 2000
Hepatic arterial therapy for the treatment of metastatic colorectal cancer. 2000
Screening and surveillance for colorectal cancer. 2000
Kaposi's sarcoma-associated herpes virus and acquired immunodeficiency syndrome-related malignancy. 2000
Gastrointestinal emergencies in the critically ill cancer patient. 2000
Infectious complications in the critically ill patient with cancer. 2000
Metabolic emergencies in the cancer patient. 2000
Neurologic emergencies in the cancer patient. 2000
Orthopedic emergencies in cancer patients. 2000
Respiratory emergencies. 2000
Urologic emergencies in the cancer patient. 2000
Contemporary approach to the classification of renal epithelial tumors. 2000
Docetaxel (Taxotere) as a single agent and in combination chemotherapy for the treatment of patients with advanced non-small cell lung cancer. 2000
Novel investigative approaches for advanced renal cell carcinoma. 2000
Renal cell carcinoma: presentation, staging, and surgical treatment. 2000
Gemcitabine in bladder cancer. 2000
Paclitaxel (Taxol) combination therapy for resistant germ cell tumors. 2000
Chemoprevention of colorectal cancer through inhibition of cyclooxygenase-2. 1999
Chemotherapy in esophageal cancer. 1999
Hepatic arterial chemotherapy in metastatic colorectal patients. 1999
Positron emission tomography imaging of colorectal cancer. 1999
Screening and surveillance for colorectal cancer. 1999
Strategies to eradicate minimal residual disease in small cell lung cancer: high-dose chemotherapy with autologous bone marrow transplantation, matrix metalloproteinase inhibitors, and BEC2 plus BCG vaccination. 1999
Peptide and carbohydrate vaccines in relapsed prostate cancer: immunogenicity of synthetic vaccines in man--clinical trials at Memorial Sloan-Kettering Cancer Center. 1999
Lymphomas of the breast: pathology and clinical behavior. 1999
Primary CNS lymphoma. 1999
Single-agent paclitaxel in the treatment of breast cancer: phase I and II development. 1999
Adjuvant breast cancer therapy: current status and future strategies--growth kinetics and the improved drug therapy of breast cancer. 1999
Gemcitabine plus taxane combinations in non-small cell lung cancer. 1999
Implementation of disease management guidelines in patients with advanced ovarian cancer. 1999
Kinetic concepts in the systemic drug therapy of breast cancer. 1999
An update on European randomized studies in non-small cell lung cancer. 1998
Gemcitabine and paclitaxel combinations in non-small cell lung cancer. 1998
The role of surgery in the management of ovarian cancer: primary and interval cytoreductive surgery. 1998
Breast-conserving surgery in the neoadjuvant setting. 1998
Management of malignant germ cell tumors of the ovary. 1998
Poor prognosis germ cell tumors: current status and future directions. 1998
Role of surgery in management of germ cell tumor. 1998
Therapy for good risk germ cell tumors. 1998
Conceptual basis for advances in the systemic drug therapy of breast cancer. 1997
Docetaxel and paclitaxel in breast cancer therapy: present status and future prospects. 1997
Evolving concepts in the systemic drug therapy of breast cancer. 1997
Topotecan and the treatment of recurrent ovarian cancer: is there a role for granulocyte colony-stimulating factor? 1997
Clinical use of posttherapy prostate-specific antigen changes in advanced prostate cancer. 1996
Targeted therapy for prostate cancer: the Memorial Sloan-Kettering Cancer Center approach. 1996
Neoadjuvant and adjuvant chemotherapy in locally advanced bladder cancer. 1996
Adjuvant drug therapy for operable breast cancer. 1996
Adjuvant and neoadjuvant therapy for gastric cancer. 1996
Surgery for gastric cancer: the American view. 1996
Chemotherapy for advanced breast cancer: a current perspective. 1996
Women's psychological reactions to breast cancer. 1996
Adjuvant chemotherapy for patients with stage II nonseminomatous testis cancer. 1995
Adjuvant therapy of upper gastrointestinal tract cancers. 1995
Memorial Sloan-Kettering Cancer Center experience with paclitaxel in the treatment of breast cancer. 1995
Treatment of chronic myelogenous leukemia. 1995
Paclitaxel in germ cell cancer. 1995
Psycho-oncology: depression, anxiety, delirium. 1994
Advances in imaging. 1994
Bioanalysis, pharmacokinetics, and pharmacodynamics of the novel anticancer drug paclitaxel (Taxol). 1994
Bone metastases: improving the therapeutic index. 1994
Current status of monoclonal antibodies for imaging and therapy of prostate cancer. 1994
Early detection of prostate cancer: the nature of cancers detected with current diagnostic tests. 1994
Methodological issues in studies of the treatment, diagnosis, and etiology of prostate cancer. 1994
Prostate cancer: improving the therapeutic index. 1994
The biological basis and clinical application of three-dimensional conformal external beam radiation therapy in carcinoma of the prostate. 1994
Combined modality therapy in the treatment of esophageal cancer. 1994
Current approaches to metastatic colorectal cancer. 1994
Salvage chemotherapy of breast cancer. 1994
The molecular basis for cellular transformation: implications for esophageal carcinogenesis. 1994
The use of chemotherapy in the treatment of advanced gastric and pancreas cancer. 1994
High-intensity chemotherapy with peripheral blood progenitor cell support. 1994
The relationship of erythropoietin and iron metabolism to red blood cell production in humans. 1994
The application of hematopoietic growth factors in advanced transitional cell carcinoma of the urinary tract. 1994
Immunophenotypic and immunogenotypic approaches useful in distinguishing benign and malignant lymphoid proliferations. 1993
Genetic analysis in the diagnosis of neoplasms of unknown primary tumor site. 1993
Phase II trials of ondansetron with high-dose cisplatin. 1992
Preclinical and clinical studies of macrophage colony-stimulating factor. 1992
Rationale for combination antiemetic therapy and strategies for the use of ondansetron in combinations. 1992
"Poor-risk" germ cell tumors: current progress and future directions. 1992
Current perspectives on the role of adjunctive surgery in combined modality treatment for patients with germ cell tumors. 1992
Modulation of fluorouracil by N-(phosphonacetyl)-L-asparate: a review. 1992
Overview of N-(phosphonacetyl)-L-aspartate + fluorouracil in clinical trials. 1992
Review of regional therapy of liver metastases in colorectal cancer. 1992
Teniposide alone and in combination chemotherapy in small cell lung cancer. 1992
The genetic and biologic aspects of treatment response and resistance in male germ cell cancer. 1992
Adjuvant therapy of upper gastrointestinal tract cancers. 1991
The evolving role of chemotherapy for muscle infiltrating bladder cancer. 1991
Studies on the mechanism of action of gallium nitrate. 1991
Chemotherapy for invasive bladder cancer: neoadjuvant versus adjuvant. 1990
Neoadjuvant chemotherapy for invasive bladder cancer: future directions. 1990
Pathology of bladder cancer: assessment of prognostic variables and response to therapy. 1990
Surgery of invasive bladder cancer: is pathologic staging necessary? 1990
Acquired immunodeficiency syndrome-associated non-Hodgkin's lymphoma. 1990
Overview of fungal infections in cancer patients. 1990
The prethrombotic state in cancer. 1990
Chemotherapy for large cell lymphoma: a status update. 1990
Immunotherapeutic approaches to the treatment of bone and soft tissue sarcomas. 1989
Cancer chemotherapy in the elderly. 1989
Host defense mechanisms and aging. 1989
Selection of patients for clinical trials. 1988
Chemotherapy in non-small cell lung cancer: results of recent trials. 1988
Genetic abnormalities as biological tumor markers. 1987
Monoclonal antibodies: potential applications to the treatment of cancer. 1986
Chemotherapy of brain tumors: physiological and pharmacokinetic considerations. 1986
Recent and current investigations of radiation therapy of malignant gliomas. 1986
Implications of kinetic heterogeneity in clinical oncology. 1985
Acute lymphoblastic leukemia in adults. 1985
Chemotherapy of esophageal cancer. 1984
Combined-modality therapy of esophageal cancer. 1984
The systemic chemotherapy of hepatic metastases. 1983
Impact of Hodgkin's disease upon the immune system. 1980
Corticosteroid therapy in patients with cerebral tumors: benefits, mechanisms, problems, practicalities. 1975

VIVO Weill Cornell Medical College

Seminars in oncology Journal

Overview

publication venue for

Identity

ISO Abbreviation

Linking ISSN

International Standard Serial Number (ISSN)

Electronic International Standard Serial Number (EISSN)